Last reviewed · How we verify
Foradil Aerolizer, Low Dose
Foradil Aerolizer, Low Dose is a Long-acting beta2-adrenergic receptor agonist Small molecule drug developed by AstraZeneca. It is currently in Phase 2 development for Chronic obstructive pulmonary disease (COPD) for bronchodilation and improved lung function. Also known as: Formoterol.
Foradil Aerolizer, a low-dose form of the drug, is a long-acting beta2-adrenergic receptor agonist that helps to open airways in the lungs.
Foradil Aerolizer, a low-dose form of the drug, is a long-acting beta2-adrenergic receptor agonist that helps to open airways in the lungs. Used for Chronic obstructive pulmonary disease (COPD) for bronchodilation and improved lung function.
At a glance
| Generic name | Foradil Aerolizer, Low Dose |
|---|---|
| Also known as | Formoterol |
| Sponsor | AstraZeneca |
| Drug class | Long-acting beta2-adrenergic receptor agonist |
| Target | Beta2-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
This is achieved by stimulating the beta2-adrenergic receptors in the smooth muscle of the bronchial tubes, leading to bronchodilation and improved airflow. This mechanism is particularly beneficial for patients with chronic obstructive pulmonary disease (COPD) or asthma.
Approved indications
- Chronic obstructive pulmonary disease (COPD) for bronchodilation and improved lung function
Common side effects
- Cough
- Dysphonia
- Headache
- Nausea
- Tremors
Key clinical trials
- Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED) (PHASE3)
- Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma (PHASE2)
- Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease (PHASE3)
- Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease (PHASE3)
- Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I (PHASE3)
- Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II (PHASE3)
- A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Foradil Aerolizer, Low Dose CI brief — competitive landscape report
- Foradil Aerolizer, Low Dose updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Foradil Aerolizer, Low Dose
What is Foradil Aerolizer, Low Dose?
How does Foradil Aerolizer, Low Dose work?
What is Foradil Aerolizer, Low Dose used for?
Who makes Foradil Aerolizer, Low Dose?
Is Foradil Aerolizer, Low Dose also known as anything else?
What drug class is Foradil Aerolizer, Low Dose in?
What development phase is Foradil Aerolizer, Low Dose in?
What are the side effects of Foradil Aerolizer, Low Dose?
What does Foradil Aerolizer, Low Dose target?
Related
- Drug class: All Long-acting beta2-adrenergic receptor agonist drugs
- Target: All drugs targeting Beta2-adrenergic receptor
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) for bronchodilation and improved lung function
- Also known as: Formoterol
- Compare: Foradil Aerolizer, Low Dose vs similar drugs
- Pricing: Foradil Aerolizer, Low Dose cost, discount & access